Rallybio Valeur comptable tangible par action

Que fait Rallybio ? Rallybio Corp is a biotechnology company headquartered in New Haven, Connecticut. It focuses on the research, development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company employs 44 full-time employees. Rallybio Corp went public on July 29, 2021. Its pipeline includes RLYB212, RLYB116, RLYB114, RLYB331, and the ENPP1 Program. RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). RLYB116 is a complement component 5 inhibitor for treating conditions such as paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio est l'une des entreprises les plus populaires sur Eulerpool.